Alfredo Arroyo : Regarding the guidance, as you know, the growth is very important to understand that it’s based on the baseline, okay, the previous year and also on — when you look at on a reported basis on the FX. For the Q4, we expect that we still expect a strong quarter, but the reality is that when we look at the amount, the amount of the fourth quarter is going to be higher than the previous quarter. However, the baseline varies from one quarter to another quarter when you compare with previous year. But said that, we reiterate this range for net revenue guidance for the year end.
Nuria Pascual : We are coming close to the hour, but we have 2 follow-ups, one from Jaime, another from Charles. Please, if you can make kind of one question each so that we conclude with that session. First, Jaime.
Jaime Escribano : Mine is fairly quick. It is regarding the pipeline. So you announced the Alzheimer’s vaccine results first readout quite recently. Just to know what could we expect following steps? And is this a big opportunity for you? Or can you try to give us some kind of sense how excited you are with this? And just a very quick one also related with the pipeline, which is the ASFA in 2018 said that they were going to review the guidelines and that in 2023, they would start recommending again products. Is this something that could be on the table again to try to revive the AMBAR project with ASFA or you don’t have a lot of expectations on that?
Victor Grifols Deu: Yes, on the Alzheimer’s, the Araclon vaccine, there was a question previous, and yes, it’s a program that we are open to out-license the financing of this Phase III trial that it should go now. So that’s the status as of today on Grifols regarding this vaccine looking for a kind of a partnership here. On the ASFA inclusion of the AMBAR protocol into their guidelines, yes, it has been included in one of the guidelines. So now that it’s a procedure that can be used out there for patients. Regarding the AMBAR in general for Grifols, we are kind of in a standby mode. We are in talks with regulatory agencies to see opportunities on how to proceed. But to the ASFA question, yes, it has been included.
Jaime Escribano : Okay. I’m sorry, Victor, just 2 follow-ups. But then is there any opportunity to monetize AMBAR through this recommendation of the ASFA or to get it into the insurance or any growth potential coming from there?
Victor Grifols Deu: At this stage, we are, let’s say, moving cautiously, I should say, in the sense of a slow, okay? We are trying to understand which are the potential possibilities that we can see for this program in relation with the inclusion of the protocol in the ASFA guidance — guidelines.
Nuria Pascual : Okay. And last question for our today’s session, Charles. Hello, Charles Pitman?
Charles Pitman : Just very quickly, can I just — want to just to get the understanding clear. The $1.5 billion you expect to receive and to pay down that’s a post-tax amount? And then just the actual question I had follow-up was just talking about the expected potential for other cost savings given you’ve now hit the kind of top end of your target for FY ’23. Kind of what other further levers are there that you’re seeking to identify going forward? Or is the focus very much just on normal operational efficiency?
Alfredo Arroyo : Okay. For the $1.5 billion, this is — it’s going to be cash, no taxes when you receive the cash, there is no taxes on this. And then regarding the operational improvement plan, as we said, this year, we’re going to achieve through P&L, the €150 million, plus the €300 million, as I said, for next year, the €450 million, I think that we continue working to exceed that €450 million. There are some opportunities already mentioned by Victor on the manufacturing side. So this is a nonstop, I would say, working. And I’m pretty sure that more savings will come in the upcoming quarters.
Nuria Pascual : Thank you, Alfredo, and thank you, everybody, for joining us today, and I expect to talk to you very soon. As always, any follow-up, any other questions you may have, you can contact us at the Investor Relations and Sustainability department, and we’ll be happy to take other questions also from all participants. Thank you very much.
Thomas Glanzmann : Thank you very much, everybody.
Victor Grifols Deu : Thank you. Bye, bye.
Alfredo Arroyo : Thank you. Bye, bye.
